Logo

Pfizer's Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC's Advisory Committee Recommendation for Invasive Disease and Pneumonia

Share this

Pfizer's Prevnar 20 (Pneumococcal 20-Valent Conjugate Vaccine) Receives the CDC's Advisory Committee Recommendation for Invasive Disease and Pneumonia

Shots:

  • The CDC’s ACIP has voted to recommend Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) to protect adults against invasive disease and pneumonia caused by the 20 S. pneumoniae serotypes
  • The ACIP has recommended one dose of Prevnar 20 for adults aged ≥65 & for ≥19yrs. with risk conditions who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown. If PCV15 is used- it should be followed by a dose of PPSV23
  • On June 8- 2021- the US FDA has approved Prevnar 20 for the prevention of invasive disease and pneumonia in adults aged ≥18yrs. and Prevnar 20 is currently under EMA’s CHMP review

 Ref: Pfizer | Image: The Wall Street Journal

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions